12-Month Study of CPAP Treatment and Lifestyle Changes on Lipids and Uric Acid in Adults With Dyslipidemia and Moderate to Severe Sleep Apnea

What this Trial Is About

Researchers are evaluating the effect of 12 months of continuous positive airway pressure CPAP treatment combined with conventional pharmacological therapy on lipid profiles in patients with dyslipidemia and moderate to severe obstructive sleep apnea OSA. This phase IV randomized, open-label, parallel clinical trial aims to explore improvements in blood lipid levels, serum uric acid, insulin resistance, cardiovascular risk, glycemic control, inflammation markers, and quality of life in this patient group aged 35 to 80 years. Participants will be randomly assigned to one of two groups one receiving standard hygienic-dietary advice and promotion of daily physical activity, and the other receiving the same plus CPAP therapy. CPAP treatment starts with an empirical pressure of 8 cmH2O and is adjusted within three weeks via automatic titration to a pressure corresponding to the 95th percentile. Patients in both groups will be encouraged to walk 10,000 steps daily, monitored with pedometers and step logs. During the 12-month study, patients will undergo assessments including blood tests for cholesterol, triglycerides, glucose, inflammatory and oxidative stress markers, and hormones related to appetite. Questionnaires on sleepiness, quality of life, and physical activity will also be completed. CPAP compliance, adverse events, and cardiovascular events will be monitored to evaluate safety and treatment effects over the study period ending in January 2028.

CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea